Na Cocer Peptides 
1 mahina aku nei
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.
Nānā nui
ʻO Tirzepatid, kahi lāʻau lapaʻau hou, ua loaʻa i ka manaʻo nui i ke kahua o ka mālama ʻana i ka maʻi diabetes. ʻO ia ka mua o ka honua agonist lua o ka glucagon-like peptide-1 (GLP-1) receptor a me ka glucose-dependent insulinotropic polypeptide (GIP) receptor. Ma o kāna hana kū hoʻokahi o ka hana, hoʻohālike ia i nā hopena kūlohelohe o GLP-1 a me GIP, e hāʻawi ana i kahi koho hou no ka mālama ʻana i ka glucose koko.
Kiʻi 1 Nā hana o ka Tirzepatid i loko o ke kino kanaka.
Mechanism of Action
Hoʻoponopono i ka insulin a me ka huna ʻana o ka glucagon: Hoʻonui ʻo Tirzepatid i ka huna ʻana o ka insulin a hoʻemi i ka hoʻokuʻu ʻana o ka glucagon ma ke ʻano pili i ka glucose. Ke piʻi aʻe ke kiʻekiʻe o ka glucose i ke koko, ʻo Tirzepatid e koi aku i nā cell beta pancreatic e hūnā i ka insulin hou aʻe, ma laila e hoʻonui ai i ka lawe ʻana a me ka hoʻohana ʻana a me ka hoʻohaʻahaʻa ʻana i nā pae glucose koko; ke pale nei i ka huna ʻana o ka glucagon, e hōʻemi ana i ka hoʻopuka ʻana o ka glucose hepatic, e hoʻopaʻa hou i nā pae glucose koko. ʻO kēia ala hoʻoponopono ʻelua-pronged e kōkua i ka mālama ʻana i ke koena glucose koko ikaika, me ka hoʻohaʻahaʻa pono ʻana i nā pae glucose koko hoʻokē ʻai a me ka postprandial.
Hoʻoulu i ka māʻona a me ka poho kaumaha: Hiki i kēia lāʻau lapaʻau ke hoʻoikaika i ka māʻona, alakaʻi i nā mea maʻi e hōʻemi i ka ʻai ʻana a ma laila e lilo ai ke kaumaha. He mea koʻikoʻi ka pohō kaumaha no nā poʻe maʻi me ka maʻi maʻi type 2, no ka mea, pili pinepine ka momona me ka pale ʻana i ka insulin. Ma ka hōʻemi ʻana i ke kaumaha, kōkua ʻo Tirzepatid i ka hoʻomaikaʻi ʻana i ka naʻau o ka insulin, e ʻoi aku ka pane ʻana o ke kino i ka insulin a no laila ʻoi aku ka maikaʻi o ka mālama ʻana i nā pae glucose koko. Hoʻohui, kōkua ka pohō kaumaha e hōʻemi i ka hopena o nā pilikia e like me ka maʻi cardiovascular i nā maʻi maʻi diabetes.
Hoʻopaneʻe ka hoʻokuʻu ʻana o ka ʻōpū: Hoʻopaneʻe ʻo Tirzepatid i ka hoʻokaʻawale ʻana o ka ʻōpū, hoʻolōʻihi i ka manawa e noho ai ka meaʻai i loko o ka ʻōpū a hoʻolōʻihi i kona komo ʻana i loko o ka ʻōpū liʻiliʻi, a laila e pale ai i ka piʻi wikiwiki ʻana o ke kō koko koko. Kōkua kēia hopena i ka hoʻopaʻa ʻana i ke kōpaʻa koko, ʻoi aku ka maikaʻi o ka hoʻomalu ʻana i ka piʻi ʻana o ke kō koko postprandial, e hana ana i nā kūlana maikaʻi no ka mālama ʻana i ke kō koko.
Hoʻomaikaʻi i nā hōʻailona metabolic: Ma kahi o kāna mau hopena i ke kō koko a me ke kaumaha, hōʻike pū ʻo Tirzepatid i nā hopena maikaʻi i ka hoʻomaikaʻi ʻana i nā pae lipid a me nā hōʻailona metabolic ʻē aʻe. Hōʻike nā haʻawina haukaʻi e kōkua ana ia e hoʻohaʻahaʻa i ka lipoprotein haʻahaʻa haʻahaʻa (LDL) cholesterol a me nā pae triglyceride, hoʻonui i ke olakino metabolic holoʻokoʻa a hoʻemi hou i ka hopena o ka maʻi cardiovascular i nā maʻi maʻi maʻi.
Palapala noi
I loko o ka SURPASS a me SURMOUNT nui-scale Phase III noiʻi lapaʻau, Tirzepatid hōʻike 'oi aku ka maikaʻi hoʻomalu glucose koko. Hoʻohālikelike ʻia me kahi placebo, ua hoʻemi nui ʻo Tirzepatid i ka pae hemoglobin A1c (HbA1c) ʻoiai e hōʻike ana i nā hopena hoʻemi kaumaha maikaʻi loa. ʻOi aku ka maikaʻi ma mua o nā agonists receptor GLP-1 i ʻae ʻia i kēia manawa. I kekahi mau ho'āʻo, ua ʻike nā mea maʻi i mālama ʻia me Tirzepatid i ka hoʻohaʻahaʻa nui ʻana i nā pae HbA1c a ʻoi aku ka nui o ka pohō kaumaha, e hōʻike pono ana i kona pono a me ka maikaʻi o ka mana glycemic a me ka mālama kaumaha.
ʻO ka mālama ʻana i ka maʻi maʻi type 2: ma ke ʻano he mea hoʻohui i ka meaʻai a me ka hoʻomaʻamaʻa, hāʻawi ʻo Tirzepatid i kahi koho lapaʻau kūpono no nā poʻe maʻi me ka maʻi diabetes type 2. Inā hoʻohana ʻia e like me ka monotherapy a i hui pū ʻia me nā lāʻau lapaʻau antidiabetic ʻē aʻe, hoʻomaikaʻi nui ʻo Tirzepatid i ka mana glucose koko o nā maʻi.
Ka hopena
I ka hōʻuluʻulu ʻana, hōʻike ʻo Tirzepatid i nā pōmaikaʻi i ka mālama ʻana i ka glucose koko ma muli o kāna hana kūʻokoʻa o ka hana a me ka hana koʻikoʻi i nā hoʻokolohua lapaʻau. ʻAʻole wale ia e hoʻohaʻahaʻa i ke kiʻekiʻe o ka glucose i ke koko akā he hana maikaʻi nō hoʻi i ka mālama paona a me ka hoʻomaikaʻi ʻana i nā hōʻailona metabolic.
Nā kumu
[1] Sood A, Kaur P, Syed O, et al. Hoʻololi i ka mālama maʻi diabetes: wehe i ka hiki o tirzepatide i ka mana glycemic a ma waho aʻe [J]. Ka Manaʻo Manaʻo o Clinical Pharmacology, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.
[2] Wong E, Cope R, Dima L, et al. ʻO Tirzepatid: He ʻelua Glucose-dependent Insulinotropic Polypeptide a me Glucagon-Like Peptide-1 Agonist no ka mālama ʻana i ke ʻano 2 Diabetes Mellitus [J]. American Journal of Therapeutics, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.
[3] Kumar D, Harshidha D, Mousigan M, et al. He Manaʻo ma luna o Tirzepatid, ʻelua-Targeted Lapaʻau no ka maʻi diabetes a me ka momona [J]. Ka Nupepa International of Innovative Research & Growth, 2022,7:983.DOI:10.5281/zenodo.7420605.
[4] Chavda VP, Ajabiya J, Teli D, et al. ʻO Tirzepatid, kahi manawa hou o ka lāʻau lapaʻau pālua ʻelua no ka maʻi maʻi a me ka momona: kahi hōʻike liʻiliʻi [J]. Nā Molekula, 2022,27(13).DOI:10.3390/molecules27134315.
[5] Forzano I, Varzideh F, Avvisato R, et al. Tirzepatid: He Hōʻano Hou [J]. Ka Nupepa International of Molecular Sciences, 2022,23(23).DOI:10.3390/ijms232314631.
Loaʻa ka huahana no ka noiʻi wale nō:
